Acute Surgical Safety of Pediatric Vagus Nerve Stimulation: A 200-Patient Consecutive Series with Literature Benchmarking

Purpose: While vagus nerve stimulation (VNS) remains a foundational neuromodulatory intervention for drug-resistant epilepsy (DRE), reported rates of acute complications, specifically infection and device removal, exhibit significant variability across pediatric cohorts. This investigation seeks to characterize the acute surgical safety profile within a single-surgeon consecutive series of 200 children and provide contextualization through structured literature benchmarking. Methods A retrospective analysis was performed on 200 consecutive pediatric patients (age <20 years) undergoing primary VNS implantation for DRE between August 2017 and January 2025. Primary endpoints included surgical site infection and device explantation within a 90-day postoperative interval, with minor perioperative events analyzed as secondary outcomes. To establish a comparative framework, a structured review of literature published from 2000 to 2024 was conducted to derive pooled aggregate rates of postoperative infection and explantation. Results In our institutional cohort of 200 patients (range 1.4–19.8 years), no surgical site infections or device explantations occurred within 90 days (0%; exact 95% CI, 0–1.83% for each outcome). Minor, transient adverse events included temporary hoarseness (2%) and cough (1.5%). The benchmarking review included 50 studies; pediatric-exclusive cohorts had sample-size-weighted infection and explantation rates of 3.15% and 4.41%, respectively. Conclusion Primary VNS implantation in the pediatric population can be achieved with an excellent acute safety profile. The total absence of infection and explantation in this large series compares favorably to literature benchmarks. These data reinforce the safety of VNS in children and suggest that meticulous surgical technique and standardized perioperative care may minimize hardware-related morbidity.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-19
DOI
https://doi.org/10.21203/rs.3.rs-11134191/v1
Primary Topic
Vagus Nerve Stimulation Research
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Acute Surgical Safety of Pediatric Vagus Nerve Stimulation: A 200-Patient Consecutive Series with Literature Benchmarking

Benjamin C. Kennedy, Susan E. Melamed, Kathleen Galligan, Rakesh A. Murugesan et al.
Research Square
Vagus Nerve Stimulation Research
preprint

Acute Surgical Safety of Pediatric Vagus Nerve Stimulation: A 200-Patient Consecutive Series with Literature Benchmarking

Benjamin C. Kennedy, Susan E. Melamed, Kathleen Galligan, Rakesh A. Murugesan, Samuel Tomlinson, Krish Upadhyay
preprint en

Abstract

Purpose: While vagus nerve stimulation (VNS) remains a foundational neuromodulatory intervention for drug-resistant epilepsy (DRE), reported rates of acute complications, specifically infection and device removal, exhibit significant variability across pediatric cohorts. This investigation seeks to characterize the acute surgical safety profile within a single-surgeon consecutive series of 200 children and provide contextualization through structured literature benchmarking. Methods A retrospective analysis was performed on 200 consecutive pediatric patients (age <20 years) undergoing primary VNS implantation for DRE between August 2017 and January 2025. Primary endpoints included surgical site infection and device explantation within a 90-day postoperative interval, with minor perioperative events analyzed as secondary outcomes. To establish a comparative framework, a structured review of literature published from 2000 to 2024 was conducted to derive pooled aggregate rates of postoperative infection and explantation. Results In our institutional cohort of 200 patients (range 1.4–19.8 years), no surgical site infections or device explantations occurred within 90 days (0%; exact 95% CI, 0–1.83% for each outcome). Minor, transient adverse events included temporary hoarseness (2%) and cough (1.5%). The benchmarking review included 50 studies; pediatric-exclusive cohorts had sample-size-weighted infection and explantation rates of 3.15% and 4.41%, respectively. Conclusion Primary VNS implantation in the pediatric population can be achieved with an excellent acute safety profile. The total absence of infection and explantation in this large series compares favorably to literature benchmarks. These data reinforce the safety of VNS in children and suggest that meticulous surgical technique and standardized perioperative care may minimize hardware-related morbidity.

Research Square
Children's Hospital of Philadelphia (US), University of Pennsylvania (US)
Vagus Nerve Stimulation Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon